Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14752MR)

This product GTTS-WQ14752MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14752MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ522MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ3566MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ14749MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ9864MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ12277MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ3037MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ1264MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ15865MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW